Intrexon Corp (XON) 46.11 $XON
Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection
PR Newswire - Thu Mar 19, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Fibrocell Science Appoints Keith A. Goldan, Senior Vice President and Chief Financial Officer
GlobeNewswire - Wed Mar 18, 3:05PM CDT
Fibrocell Science, Inc. (Nasdaq:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced the appointment of Keith A. Goldan as Senior Vice President and Chief Financial Officer (CFO), effective immediately. Mr. Goldan offers more than 20 years of executive finance and operational leadership in biopharmaceutical and medical technology companies.
FCSC: 5.48 (-0.14), XON: 46.11 (-1.26), TEVA: 62.10 (+0.55)
Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights
PR Newswire - Mon Mar 16, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today reported financial results for the year ended December 31, 2014, and provided an operational update.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.59 (+0.06), ZIOP: 13.89 (-0.11), UNIS: 3.63 (-0.01), FCSC: 5.48 (-0.14), XON: 46.11 (-1.26), MNKD: 5.26 (-0.28)
Fibrocell Science Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
GlobeNewswire - Fri Mar 13, 7:10AM CDT
- Significant progress advancing gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB), a devastating and progressive orphan skin disease -
FCSC: 5.48 (-0.14), XON: 46.11 (-1.26)
Intrexon (XON) Upgraded From Sell to Hold
at The Street - Wed Mar 11, 1:43PM CDT
Intrexon (XON) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
XON: 46.11 (-1.26)
Increased Earnings Estimates Seen for Intrexon (XON): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 7:53AM CDT
Intrexon could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
XON: 46.11 (-1.26)
AmpliPhi Bio raises $13M in new capital
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 6:40AM CDT
XON: 46.11 (-1.26)
Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine
PR Newswire - Wed Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating complete protection and immunogenicity of its ricin vaccine, RiVax(TM), in preclinical studies, with analyses of previous human clinical samples. RiVax(TM) employs a derivative of recombinant ricin toxin A chain. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM) has been previously demonstrated to enhance thermostability of RiVax(TM), enabling distribution without cold chain requirements. In this work, vaccination with RiVax(TM) provided 100% protection for non-human primates (NHPs) subsequently exposed to lethal doses of aerosolized ricin. Evaluation of antibodies produced by the NHPs after vaccination identified specific neutralizing antibodies which were also expressed by humans previously vaccinated with RiVax(TM). The results were published online in the Proceedings of the National Academy of Sciences and are available at the following link: http://www.pnas.org/content/early/2015/03/05/...f32229914c .
XON: 46.11 (-1.26)
Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015
PR Newswire - Wed Mar 11, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-004, the Company's candidate therapy designed to degrade intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, will be presented during Digestive Disease Week® (DDW) 2015 in Washington DC on May 16-19.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
AmpliPhi BioSciences concludes USD13m financing
M2 - Wed Mar 11, 5:26AM CDT
Bacteriophage therapies company AmpliPhi BioSciences (OtherOTC:APHB) announced on Tuesday that it expects to raise approximately USD13m in a private placement financing of common stock and warrants with both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE:XON).
XON: 46.11 (-1.26)
Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 124.76 (-1.64), ZIOP: 13.89 (-0.11), PFE: 34.25 (+0.10), XON: 46.11 (-1.26), AMGN: 170.10 (+0.99), GSK: 48.81 (+0.60), IMUC: 0.57 (-0.01), CELG: 128.50 (+3.17), JNJ: 102.40 (+0.71), BLCM: 25.19 (-0.71), KITE: 71.89 (-1.62), JUNO: 61.53 (+1.85), NVS: 101.68 (+1.81)
AmpliPhi BioSciences Corporation Announces $13 Million Financing
Business Wire - Tue Mar 10, 4:07PM CDT
AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, including both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE: XON), to raise approximately $13,000,000 in a private placement financing. Pursuant to the purchase agreements, the Company will issue an aggregate of 78,787,880 shares of the Company's common stock at a price per share of $0.165, as well as the sale and issuance of warrants to purchase 0.25 shares of common stock for each share of common stock per warrant share. The warrants, which represent the right to purchase an aggregate of 19,696,971 shares of common stock, expire in March 2020 and will be exercisable at a price of $0.215 per share. The warrants will be exercisable beginning on the later of (i) the first anniversary of the date of issuance and (ii) the date AmpliPhi effects a reverse stock split or increases the number of authorized shares of common stock, in either case in an amount sufficient to permit the exercise in full of the warrants issued in this offering. If the reverse stock split or share increase occurs before the first anniversary, the warrants will be exercisable at that time.
XON: 46.11 (-1.26)
Synthetic Biologics to Report Year End 2014 Financial Results
PR Newswire - Mon Mar 09, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the year ended December 31, 2014 on Monday, March 16, 2015. The Company will also hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Intrexon (XON) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 6:07AM CST
Intrexon (XON) Shares March Higher, Can It Continue?
XON: 46.11 (-1.26)
Can Intrexon Corp's Jaw-Dropping Growth Continue after Tuesday's 20% Jump?
Maxx Chatsko, The Motley Fool - Motley Fool - Thu Mar 05, 8:12AM CST
Image source: John Goode/ Flickr . Who said fame only lasts for 15 minutes? Already on a tear entering 2015, synthetic biology leader Intrexon roared higher after reporting full-year 2014 earnings earlier this week. A little over two months...
ZIOP: 13.89 (-0.11), XON: 46.11 (-1.26)
Why Intrexon Corp Catapulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 3:10PM CST
Source: Intrexon Corporation Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intrexon...
ZIOP: 13.89 (-0.11), XON: 46.11 (-1.26)
Intrexon ups revenues 338% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:27AM CST
XON: 46.11 (-1.26)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 3.29 (+0.01), ONCY: 0.81 (-0.02), PLUG: 2.66 (-0.05), OCN: 8.52 (+0.17), XON: 46.11 (-1.26), TEDU: 10.39 (+0.16), BIOC: 2.45 (-0.12), LL: 28.51 (-0.84), MNKD: 5.26 (-0.28), CYCC: 0.98 (+0.02), CYTX: 1.19 (-0.03), DATE: 5.10 (unch), TSEM: 17.82 (-0.01), LEAF: 53.27 (+0.41), FNJN: 2.03 (-0.05), AMCO: 1.27 (+0.02)
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PR Newswire - Tue Mar 03, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population.
XON: 46.11 (-1.26)
Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection
PR Newswire - Thu Mar 19, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Fibrocell Science Appoints Keith A. Goldan, Senior Vice President and Chief Financial Officer
GlobeNewswire - Wed Mar 18, 3:05PM CDT
Fibrocell Science, Inc. (Nasdaq:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced the appointment of Keith A. Goldan as Senior Vice President and Chief Financial Officer (CFO), effective immediately. Mr. Goldan offers more than 20 years of executive finance and operational leadership in biopharmaceutical and medical technology companies.
FCSC: 5.48 (-0.14), XON: 46.11 (-1.26), TEVA: 62.10 (+0.55)
Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights
PR Newswire - Mon Mar 16, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today reported financial results for the year ended December 31, 2014, and provided an operational update.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.59 (+0.06), ZIOP: 13.89 (-0.11), UNIS: 3.63 (-0.01), FCSC: 5.48 (-0.14), XON: 46.11 (-1.26), MNKD: 5.26 (-0.28)
Fibrocell Science Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
GlobeNewswire - Fri Mar 13, 7:10AM CDT
- Significant progress advancing gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB), a devastating and progressive orphan skin disease -
FCSC: 5.48 (-0.14), XON: 46.11 (-1.26)
Intrexon (XON) Upgraded From Sell to Hold
at The Street - Wed Mar 11, 1:43PM CDT
Intrexon (XON) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
XON: 46.11 (-1.26)
Increased Earnings Estimates Seen for Intrexon (XON): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 7:53AM CDT
Intrexon could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
XON: 46.11 (-1.26)
AmpliPhi Bio raises $13M in new capital
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 6:40AM CDT
XON: 46.11 (-1.26)
Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine
PR Newswire - Wed Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating complete protection and immunogenicity of its ricin vaccine, RiVax(TM), in preclinical studies, with analyses of previous human clinical samples. RiVax(TM) employs a derivative of recombinant ricin toxin A chain. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM) has been previously demonstrated to enhance thermostability of RiVax(TM), enabling distribution without cold chain requirements. In this work, vaccination with RiVax(TM) provided 100% protection for non-human primates (NHPs) subsequently exposed to lethal doses of aerosolized ricin. Evaluation of antibodies produced by the NHPs after vaccination identified specific neutralizing antibodies which were also expressed by humans previously vaccinated with RiVax(TM). The results were published online in the Proceedings of the National Academy of Sciences and are available at the following link: http://www.pnas.org/content/early/2015/03/05/...f32229914c .
XON: 46.11 (-1.26)
Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015
PR Newswire - Wed Mar 11, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-004, the Company's candidate therapy designed to degrade intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, will be presented during Digestive Disease Week® (DDW) 2015 in Washington DC on May 16-19.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
AmpliPhi BioSciences concludes USD13m financing
M2 - Wed Mar 11, 5:26AM CDT
Bacteriophage therapies company AmpliPhi BioSciences (OtherOTC:APHB) announced on Tuesday that it expects to raise approximately USD13m in a private placement financing of common stock and warrants with both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE:XON).
XON: 46.11 (-1.26)
Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 124.76 (-1.64), ZIOP: 13.89 (-0.11), PFE: 34.25 (+0.10), XON: 46.11 (-1.26), AMGN: 170.10 (+0.99), GSK: 48.81 (+0.60), IMUC: 0.57 (-0.01), CELG: 128.50 (+3.17), JNJ: 102.40 (+0.71), BLCM: 25.19 (-0.71), KITE: 71.89 (-1.62), JUNO: 61.53 (+1.85), NVS: 101.68 (+1.81)
AmpliPhi BioSciences Corporation Announces $13 Million Financing
Business Wire - Tue Mar 10, 4:07PM CDT
AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, including both existing and new investors, as well as with its strategic alliance partner Intrexon (NYSE: XON), to raise approximately $13,000,000 in a private placement financing. Pursuant to the purchase agreements, the Company will issue an aggregate of 78,787,880 shares of the Company's common stock at a price per share of $0.165, as well as the sale and issuance of warrants to purchase 0.25 shares of common stock for each share of common stock per warrant share. The warrants, which represent the right to purchase an aggregate of 19,696,971 shares of common stock, expire in March 2020 and will be exercisable at a price of $0.215 per share. The warrants will be exercisable beginning on the later of (i) the first anniversary of the date of issuance and (ii) the date AmpliPhi effects a reverse stock split or increases the number of authorized shares of common stock, in either case in an amount sufficient to permit the exercise in full of the warrants issued in this offering. If the reverse stock split or share increase occurs before the first anniversary, the warrants will be exercisable at that time.
XON: 46.11 (-1.26)
Synthetic Biologics to Report Year End 2014 Financial Results
PR Newswire - Mon Mar 09, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the year ended December 31, 2014 on Monday, March 16, 2015. The Company will also hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Intrexon (XON) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 6:07AM CST
Intrexon (XON) Shares March Higher, Can It Continue?
XON: 46.11 (-1.26)
Can Intrexon Corp's Jaw-Dropping Growth Continue after Tuesday's 20% Jump?
Maxx Chatsko, The Motley Fool - Motley Fool - Thu Mar 05, 8:12AM CST
Image source: John Goode/ Flickr . Who said fame only lasts for 15 minutes? Already on a tear entering 2015, synthetic biology leader Intrexon roared higher after reporting full-year 2014 earnings earlier this week. A little over two months...
ZIOP: 13.89 (-0.11), XON: 46.11 (-1.26)
Why Intrexon Corp Catapulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 3:10PM CST
Source: Intrexon Corporation Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intrexon...
ZIOP: 13.89 (-0.11), XON: 46.11 (-1.26)
Intrexon ups revenues 338% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:27AM CST
XON: 46.11 (-1.26)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 3.29 (+0.01), ONCY: 0.81 (-0.02), PLUG: 2.66 (-0.05), OCN: 8.52 (+0.17), XON: 46.11 (-1.26), TEDU: 10.39 (+0.16), BIOC: 2.45 (-0.12), LL: 28.51 (-0.84), MNKD: 5.26 (-0.28), CYCC: 0.98 (+0.02), CYTX: 1.19 (-0.03), DATE: 5.10 (unch), TSEM: 17.82 (-0.01), LEAF: 53.27 (+0.41), FNJN: 2.03 (-0.05), AMCO: 1.27 (+0.02)
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PR Newswire - Tue Mar 03, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population.
XON: 46.11 (-1.26)
